Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance - Test2 - elhamkhani - TriplyDB

Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance

Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance

http://www.wikidata.org/entity/Q34144126

about

MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53 Cancer/testis antigens, gametogenesis and cancer Localization of TRAIL/TRAILR in fetal pancreas Gradually elevated expression of Gankyrin during human hepatocarcinogenesis and its clinicopathological significance The regulation of non-coding RNA expression in the liver of mice fed DDC.MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms.Characterization of the binding interaction between the oncoprotein gankyrin and a grafted S6 ATPase.Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.Gankyrin is frequently overexpressed in cervical high grade disease and is associated with cervical carcinogenesis and metastasis Identification of miR-145 targets through an integrated omics analysis.Intracellular signaling and hepatocellular carcinoma.Up-regulated oncoprotein P28GANK correlates with proliferation and poor prognosis of human glioma.Segregation analysis of hepatocellular carcinoma in a moderately high-incidence area of East China.Gene therapy strategies for hepatocellular carcinoma.Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells.Synthetic Proteins Potently and Selectively Bind the Oncoprotein Gankyrin, Modulate Its Interaction with S6 ATPase, and Suppress Gankyrin/MDM2-Dependent Ubiquitination of p53.Coping with stress: multiple ways to activate p53.Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma.Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?The impact of hypoxia in hepatocellular carcinoma metastasis.Expression of the oncoprotein gankyrin and phosphorylated retinoblastoma protein in human testis and testicular germ cell tumor.Discovery of multiple interacting partners of gankyrin, a proteasomal chaperone and an oncoprotein--evidence for a common hot spot site at the interface and its functional relevance.Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells.p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways.Overexpression of a new gene P28GANK confers multidrug resistance of gastric cancer cells.Association of gankyrin protein expression with early clinical stages and insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma.Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.Resurfaced shape complementary proteins that selectively bind the oncoprotein gankyrin.p28GANK inhibits endoplasmic reticulum stress-induced cell death via enhancement of the endoplasmic reticulum adaptive capacity.Gene and protein expressions of p28GANK in rat with liver regeneration.The role of p28GANK in rat oval cells activation and proliferation.Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma.Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.Minority stress and leukocyte gene expression in sexual minority men living with treated HIV infection.

P2860

Q24338637-B9AD2EA3-8B06-41CB-A9F8-5C6B81B76FD2 Q27488744-97BE511A-1421-456F-AEBF-5763F919BB0E Q27642398-78E05D2D-FD22-4CAE-91D7-D2BDFF9F1A6D Q29616129-42343C4F-737B-467B-9303-CBC5C148B8AC Q30881749-9B400F35-D211-474F-A37A-40D52BB0DD6B Q33851157-B16696CF-39B5-4EF0-86AF-3F29162CCAD7 Q33911063-A19C5A4D-84A5-4816-AF46-C08FD6BAE7D2 Q34264405-D201FF95-C05A-4808-BF9F-63F0F586B712 Q34502804-5DECB54B-DE48-4AA4-A394-091C05167ED0 Q34619226-83F3C1A0-2D9D-40A1-895B-D5C5BBAF31FB Q35153915-7A9F7CDF-2CAD-40F3-AAB6-94970BF021D3 Q35155627-8837673F-F899-4391-B654-C0503FD2DB7D Q35586439-46D44CD0-FBC3-4BB9-B75D-C840AE5EBAC2 Q36235734-E7D277FF-38DA-4BCD-90FF-EDF7CD91965C Q36308812-24285171-5EC2-4D8A-AB10-8EA01888A8A8 Q36457829-9D95ECDA-3005-4E77-9BA6-33F5F13D3AA1 Q36502549-54A8999D-0F9C-492E-9AE2-69F78EB0870E Q36572527-A6267B19-F612-4668-9FCD-ECD7691FD896 Q36745375-6819134E-7A08-4C62-AC93-AAAB359711B6 Q36863127-8D8032BA-C56D-4266-B93D-A5347B5B335F Q37961864-6345B84D-BAF9-48A0-B8A2-82D5833E7683 Q38162804-1900CD12-8759-4BD3-A844-7925AC06DFDC Q38991575-BC2051BC-78AD-4E0B-A509-B8B05B2B2780 Q39043145-3BA1C5E8-2D06-4645-A7BA-02509D9ED445 Q39240990-DB6CA572-6438-4BC9-A3FE-17F6C8B36CE6 Q39511329-80493663-50D6-4AF7-9AB1-8B7943A0A590 Q39604806-BBEC6840-594C-4D66-81D3-71EA1F210080 Q39880807-0C3B69AC-B1AC-41ED-A215-0C6780F4E2EF Q40030453-8521E112-227A-49BD-8599-10B8D46C910A Q41982097-EDC70E6D-F3B4-4F47-ABD8-BEC60CC0AD01 Q42548703-7B46BCB0-08C3-4696-9A72-5EC71D04338F Q42834062-40150070-D8F1-46AF-82C8-314DAD5BCA26 Q43159668-3243094F-467C-4E92-91EE-30E34AEB16B7 Q46920600-4C0BAE09-3800-4A58-A60D-CC62689DBD8F Q47661011-C05C5431-EEB9-4287-A2B4-8ECA02977E88 Q53090136-A5294E1E-2B00-4AF1-9AC8-D2BF8125D3BD Q54254509-716F7EAB-B503-4E51-9689-831E91F07933

P2860

Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance

http://www.wikidata.org/entity/Q34144126

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Overexpression of p28/gankyrin ...... and its clinical significance

@ast

Overexpression of p28/gankyrin ...... and its clinical significance

@en

Overexpression of p28/gankyrin ...... and its clinical significance

@nl

type

label

Overexpression of p28/gankyrin ...... and its clinical significance

@ast

Overexpression of p28/gankyrin ...... and its clinical significance

@en

Overexpression of p28/gankyrin ...... and its clinical significance

@nl

prefLabel

Overexpression of p28/gankyrin ...... and its clinical significance

@ast

Overexpression of p28/gankyrin ...... and its clinical significance

@en

Overexpression of p28/gankyrin ...... and its clinical significance

@nl

P1433

Q34144126-2D368796-7477-4164-B222-A8B70A52C654

P1476

Q34144126-12FC1AE7-73B0-47DD-BFD2-77342398248B

P2093

Q34144126-3838C3C3-6A7F-431F-B0C5-C8FB2C662BBE

Q34144126-478C87D6-B58F-4D07-975B-38AAECF9E54F

Q34144126-7130491D-3A6D-41E3-9D52-6FD05A19B04F

Q34144126-7CB4D2C8-3CB3-42C5-9FC0-FFE02BA7F2C9

Q34144126-960A107E-6C0B-40C4-BB39-E35085587B71

Q34144126-EFD51832-1787-4466-9008-89BA8FB8675A

P2860

Q34144126-1381242C-C8C6-454E-AA57-090D4832C2CC

Q34144126-1B23069B-ED0C-4780-BD58-E3DFE9F9A728

Q34144126-2082BDAA-7AB0-42AD-B6F3-8FF4E233A519

Q34144126-2382D5F2-4219-42B6-AFC2-33D3E9FDDCAA

Q34144126-2474E31E-C691-48AB-B851-7782A807A83B

Q34144126-3B74C881-5E84-4FF9-A4B2-6152C11FE760

Q34144126-3C194B8A-79FD-4482-98CA-BC47EBACD25F

Q34144126-4084FD73-5039-4642-A8A0-BDEB569B8B34

Q34144126-4CCCD9F6-0D6A-494F-8CC9-4B7C1BEB4FA9

Q34144126-556A286F-0630-43C0-A46B-AA07CAD900D8

P304

Q34144126-47978E22-080E-4FF0-A7F2-011C511A78B0

P31

Q34144126-DC983826-83AB-4915-8464-D66F61887627

P356

Q34144126-4206A7A5-9243-497B-AC0D-66167B9E989C

P407

Q34144126-1C8CAB07-9586-48C8-A91C-9DC34D17A80E

P433

Q34144126-CAE5EB69-61B2-46F3-9A92-EF744D81D089

P478

Q34144126-2C99EF6F-D560-4508-93D0-B224B9B07762

P577

Q34144126-3DCBD580-C168-4958-883F-511ECE06ABCB

P5875

Q34144126-32A4AC01-4D66-4362-9AAC-BC87258E31B0

P698

Q34144126-9250D642-8D14-45D9-AD9A-D593EA87CD59

P921

Q34144126-A624B142-3695-42E9-9BDF-8A043697F112

P932

Q34144126-77A2CDCF-6097-4794-96D0-9ACE1EDEE9A9

P356

P1433

World Journal of Gastroenterology

P1476

Overexpression of p28/gankyrin ...... and its clinical significance

@en

P2093

Hong-Yang Wang

http://www.w3.org/2001/XMLSchema#string

Hui-Fang Cao

http://www.w3.org/2001/XMLSchema#string

Lu Tan

http://www.w3.org/2001/XMLSchema#string

Meng-Chao Wu

http://www.w3.org/2001/XMLSchema#string

Shu-Qin Liu

http://www.w3.org/2001/XMLSchema#string

Xiao-Yong Fu

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas

Expression of nuclear factor-kappa B in hepatocellular carcinoma and its relation with the X protein of hepatitis B virus

cDNA cloning and functional analysis of p28 (Nas6p) and p40.5 (Nas7p), two novel regulatory subunits of the 26S proteasome

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

Crystal structure of the CDK4/6 inhibitory protein p18INK4c provides insights into ankyrin-like repeat structure/function and tumor-derived p16INK4 mutations

Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally?

Construction of a human full-length cDNA bank

The proteasome: paradigm of a self-compartmentalizing protease

The ubiquitin-proteasome pathway: on protein death and cell life

Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: a molecular epidemiological approach.

P304

638-643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V8.I4.638

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11213511

http://www.w3.org/2001/XMLSchema#string

P698

12174370

http://www.w3.org/2001/XMLSchema#string

P921

P932

4656312

http://www.w3.org/2001/XMLSchema#string